0001628280-24-033284 | 10-Q | XBRL Viewer

Composition of Certain Balance Sheet Items

6 Months Ended

Jun. 30, 2024

Balance Sheet Related Disclosures [Abstract]

Composition of Certain Balance Sheet Items

Inventory


	June 30, 2024		December 31, 2023

	(in thousands)
Work in progress	8,451		8,233
Finished goods	8,350		7,741
Total inventory	16,801		15,974
Less strategic inventory classified as non-current	(8,451)		(8,244)
Total inventory classified as current	$	8,350	$	7,730

We rely on two manufacturers to produce Korlym’s active pharmaceutical ingredient (“API”). We have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “strategic inventory,” a non-current asset.

Prepaid expenses and other current assets


	June 30, 2024		December 31, 2023

	(in thousands)
Deferred clinical materials	$	8,328	$	13,496
Prepaid expenses	5,146		4,319
Clinical deposits	2,903		3,865
Other current assets	9,126		5,882
Total prepaid expenses and other current assets	$	25,503	$	27,562

Accrued and other liabilities


	June 30, 2024		December 31, 2023

	(in thousands)
Government rebates	$	31,651	$	18,468
Accrued compensation	17,392		25,457
Accrued selling and marketing costs	3,535		1,771
Legal fees	1,376		542
Other	5,296		5,390
Total accrued and other liabilities	$	59,250	$	51,628

Other assets

As of June 30, 2024 and December 31, 2023, other assets included $5.9 million and $6.4 million of deposits for clinical trials, respectively.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation We have prepared the following interim financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of June 30, 2024 and (ii) condensed consolidated statements of income, comprehensive income and stockholders’ equity for the three- and six-month periods ended June 30, 2024 and 2023 and (iii) condensed consolidated statements of cash flows for the six-month periods ended June 30, 2024 and 2023. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three- and six-month periods ended June 30, 2024 are not necessarily indicative of the results for the remainder of 2024 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2023 included in our Annual Report on Form 10-K. The December 31, 2023 balance sheet was derived from audited financial statements at that date.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2025. We are currently evaluating the effects adoption of this guidance will have on the condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The standard is effective for public companies with annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2024. We are currently evaluating the effects adoption of this guidance will have on the condensed consolidated financial statements.

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 128,588	$ 135,551
Short-term marketable securities	344,568	232,670
Trade receivables, net of allowances	53,837	41,123
Insurance recovery receivable related to Melucci litigation (Note 4)	0	14,000
Inventory	8,350	7,730
Prepaid expenses and other current assets	25,503	27,562
Total current assets	560,846	458,636
Strategic inventory	8,451	8,244
Operating lease right-of-use asset	5,684	120
Property and equipment, net	1,472	195
Long-term marketable securities	19,315	57,176
Other assets	6,939	6,541
Deferred tax assets, net	111,848	90,605
Total assets	714,555	621,517
Current liabilities:
Accounts payable	19,484	17,396
Accrued research and development expenses	21,972	21,330
Accrued and other liabilities	59,250	51,628
Accrued settlement related to Melucci litigation (Note 4)	0	14,000
Short-term operating lease liability	44	151
Total current liabilities	100,750	104,505
Long-term operating lease liability	5,625	0
Long-term accrued income taxes payable	11,937	10,307
Total liabilities	118,312	114,812
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock	0	0
Common stock	134	133
Treasury stock	(650,763)	(635,078)
Additional paid-in capital	781,012	738,515
Accumulated other comprehensive income	84	609
Retained earnings	465,776	402,526
Total stockholders’ equity	596,243	506,705
Total liabilities and stockholders’ equity	$ 714,555	$ 621,517

Available-for-Sale Marketable Securities and Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2024

Available For Sale Securities And Fair Value Measurements [Abstract]

Summary of the classification of available-for-sale securities in condensed consolidated balance sheets

The available-for-sale securities in our condensed consolidated balance sheets are as follows:


	June 30, 2024		December 31, 2023

	(in thousands)
Cash equivalents	$	95,718	$	97,170
Short-term marketable securities	344,568		232,670
Long-term marketable securities	19,315		57,176
Total marketable securities	$	459,601	$	387,016

Schedule of available-for-sale securities

The following table presents our available-for-sale securities grouped by asset type:


	Fair Value Hierarchy Level	June 30, 2024								December 31, 2023
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value

		(in thousands)
Corporate bonds	Level 2	$	176,998	$	26	$	(119)	$	176,905	$	120,508	$	307	$	—	$	120,815
Commercial paper	Level 2	29,653		—		(9)		29,644		75,308		20		(9)		75,319
U.S. Treasury securities	Level 1	172,304		1		(8)		172,297		93,655		61		(4)		93,712
Money market funds	Level 1	80,755		—		—		80,755		97,170		—		—		97,170
Total marketable securities		$	459,710	$	27	$	(136)	$	459,601	$	386,641	$	388	$	(13)	$	387,016

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

+ Details

Available-for-Sale Marketable Securities and Fair Value Measurements

6 Months Ended

Jun. 30, 2024

Available For Sale Securities And Fair Value Measurements [Abstract]

Available-for-Sale Marketable Securities and Fair Value Measurements

The available-for-sale securities in our condensed consolidated balance sheets are as follows:


	June 30, 2024		December 31, 2023

	(in thousands)
Cash equivalents	$	95,718	$	97,170
Short-term marketable securities	344,568		232,670
Long-term marketable securities	19,315		57,176
Total marketable securities	$	459,601	$	387,016

The following table presents our available-for-sale securities grouped by asset type:


	Fair Value Hierarchy Level	June 30, 2024								December 31, 2023
		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value		Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value

		(in thousands)
Corporate bonds	Level 2	$	176,998	$	26	$	(119)	$	176,905	$	120,508	$	307	$	—	$	120,815
Commercial paper	Level 2	29,653		—		(9)		29,644		75,308		20		(9)		75,319
U.S. Treasury securities	Level 1	172,304		1		(8)		172,297		93,655		61		(4)		93,712
Money market funds	Level 1	80,755		—		—		80,755		97,170		—		—		97,170
Total marketable securities		$	459,710	$	27	$	(136)	$	459,601	$	386,641	$	388	$	(13)	$	387,016

We estimate the fair value of marketable securities classified as Level 1 using quoted market prices obtained from a commercial pricing service for these or identical investments. We estimate the fair value of marketable securities classified as Level 2 using inputs that may include benchmark yields, reported trades, broker/dealer quotes and issuer spreads.

We periodically review our debt securities to determine if any of our investments is impaired due to the issuer’s poor credit or other reasons. If the fair value of our investment is less than our amortized cost, we evaluate quantitative and subjective factors – including, but not limited to, the nature of security, changes in credit ratings and analyst reports concerning the security’s issuer and industry, and interest rate fluctuations and general market conditions – to determine whether an allowance for credit losses is appropriate.

None of our investments, including those with unrealized losses, are impaired. Unrealized losses on our investments are due to interest rate fluctuations. We do not intend to sell investments that currently have unrealized losses and it is highly unlikely that we will sell any investment before recovery of its amortized cost basis, which may be at maturity. Accordingly, we have not recorded an allowance for credit losses for these investments.

We classified accrued interest on our marketable securities of $2.3 million and $1.7 million as of June 30, 2024 and December 31, 2023, respectively, as prepaid and other current assets on our condensed consolidated balance sheets.

As of June 30, 2024, all of our long-term marketable securities had original maturities of no more than 26 months and all our marketable securities classified as short-term have maturities of less than one year. The weighted-average maturity of our holdings was four months. As of June 30, 2024, our long-term marketable securities had remaining maturities between 13 months and 18 months. None of our marketable securities changed from one fair value hierarchy to another during the three and six months ended June 30, 2024.

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2024

Equity [Abstract]

Summary of stock-based compensation

The following table summarizes our stock-based compensation by account:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

	(in thousands)
Capitalized stock-based compensation	$	83	$	34	$	128	$	126
Cost of sales	14		9		25		32
Research and development	4,437		3,661		8,358		7,145
Selling, general and administrative	10,756		8,188		20,073		15,822
Total stock-based compensation	$	15,290	$	11,892	$	28,584	$	23,125

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Beginning balance (in shares) at Dec. 31, 2022		107,835
Beginning balance at Dec. 31, 2022	$ 501,842	$ 131	$ 662,342	$ (456,148)	$ (869)	$ 296,386
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under our incentive award plan (in shares)		618
Issuance of common stock under incentive award plan	6,540		6,540
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock (in shares)		(297)
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock	(6,359)			(6,359)
Stock-based compensation	10,966		10,966
Other comprehensive income (loss), net of tax	716				716
Net income	15,879					15,879
Ending balance (in shares) at Mar. 31, 2023		108,156
Ending balance at Mar. 31, 2023	529,584	$ 131	679,848	(462,507)	(153)	312,265
Beginning balance (in shares) at Dec. 31, 2022		107,835
Beginning balance at Dec. 31, 2022	501,842	$ 131	662,342	(456,148)	(869)	296,386
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	43,407
Ending balance (in shares) at Jun. 30, 2023		102,512
Ending balance at Jun. 30, 2023	421,614	$ 132	695,718	(614,074)	45	339,793
Beginning balance (in shares) at Mar. 31, 2023		108,156
Beginning balance at Mar. 31, 2023	529,584	$ 131	679,848	(462,507)	(153)	312,265
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under our incentive award plan (in shares)		1,168
Issuance of common stock under incentive award plan	4,497	$ 1	4,496
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock (in shares)		(202)
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock	(4,823)		0	(4,823)
Repurchase of common stock in connection with Stock Repurchase Program (in shares)		(6,610)
Repurchase of common stock in connection with Stock Repurchase Program	(145,428)			(145,428)
Excise tax related to net share repurchases	(1,316)			(1,316)
Stock-based compensation	11,374		11,374
Other comprehensive income (loss), net of tax	198				198
Net income	27,528					27,528
Ending balance (in shares) at Jun. 30, 2023		102,512
Ending balance at Jun. 30, 2023	421,614	$ 132	695,718	(614,074)	45	339,793
Beginning balance (in shares) at Dec. 31, 2023		103,405
Beginning balance at Dec. 31, 2023	506,705	$ 133	738,515	(635,078)	609	402,526
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under our incentive award plan (in shares)		786
Issuance of common stock under incentive award plan	3,485		3,485
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock (in shares)		(143)
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock	(3,554)		2,032	(5,586)
Repurchase of common stock in connection with Stock Repurchase Program (in shares)		(20)
Repurchase of common stock in connection with Stock Repurchase Program	(476)			(476)
Excise tax related to net share repurchases	81			81
Stock-based compensation	12,929		12,929
Vesting of RSAs in connection with ESPP	1,283		1,283
Other comprehensive income (loss), net of tax	(351)				(351)
Net income	27,762					27,762
Ending balance (in shares) at Mar. 31, 2024		104,028
Ending balance at Mar. 31, 2024	547,864	$ 133	758,244	(641,059)	258	430,288
Beginning balance (in shares) at Dec. 31, 2023		103,405
Beginning balance at Dec. 31, 2023	506,705	$ 133	738,515	(635,078)	609	402,526
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	63,250
Ending balance (in shares) at Jun. 30, 2024		104,398
Ending balance at Jun. 30, 2024	596,243	$ 134	781,012	(650,763)	84	465,776
Beginning balance (in shares) at Mar. 31, 2024		104,028
Beginning balance at Mar. 31, 2024	547,864	$ 133	758,244	(641,059)	258	430,288
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under our incentive award plan (in shares)		700
Issuance of common stock under incentive award plan	7,574		7,573
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock (in shares)		(208)
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock	(6,242)			(6,242)
Repurchase of common stock in connection with Stock Repurchase Program (in shares)		(122)
Repurchase of common stock in connection with Stock Repurchase Program	(3,478)			(3,478)
Excise tax related to net share repurchases	16			16
Stock-based compensation	13,881		13,881
Vesting of RSAs in connection with ESPP	1,314		1,314
Other comprehensive income (loss), net of tax	(174)				(174)
Net income	35,488					35,488
Ending balance (in shares) at Jun. 30, 2024		104,398
Ending balance at Jun. 30, 2024	$ 596,243	$ 134	$ 781,012	$ (650,763)	$ 84	$ 465,776

Leases

6 Months Ended

Jun. 30, 2024

Leases [Abstract]

Leases

On April 12, 2024, we entered into a six-year sublease (the “Sublease”) with Zuora, Inc. for office space located at 101 Redwood Shores Parkway, Redwood City, California, effective from July 1, 2024. The leased property will serve as our new headquarters effective August 1, 2024. The portion of the premises subject to the Sublease is 50,632 rentable square feet. The Sublease commenced on June 1, 2024 due to early access rights and will end on June 30, 2030. We are obligated to pay a base rent of an average of $1.5 million annually over the term of the lease. As a result of the agreement, we recorded a right-of-use asset and corresponding lease liability related to the leased property based on the present value of future lease payments.

On May 13, 2024, we entered into an amendment to extend the lease for our current headquarters in Menlo Park, California through August 31, 2024. We do not recognize right-of-use assets or lease liabilities for leases with a term of 12 months or less, rather, we recognize the associated lease payments in the condensed consolidated statements of income on a straight-line basis over the lease term. Therefore, we did not record an additional right of use asset and corresponding lease liability related to our current headquarters, as the remaining lease term is less than 12 months.

As the operating leases for our facilities do not provide sufficient information to determine the implicit borrowing rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the monthly payments and remaining term of our lease. Operating lease right-of-use assets also include any rent paid prior to the commencement date, less any lease incentives received. We recognize operating lease payments as expenses using the straight-line method over the term of the lease.

Operating lease expense for the three and six months ended June 30, 2024 was $0.8 million and $1.4 million, respectively, compared to $0.6 million and $1.2 million, respectively, for the comparable periods in 2023.

Supplemental information related to operating leases was as follows (in thousands, except weighted average amounts):


	Three months ended June 30,				Six months ended June 30,
	2024		2023		2024			2023
Cash paid for operating lease liabilities	$	741	$	578	$	1,358		$	1,157
Recognition of right-of-use asset in exchange for lease liability	$	5,745	$	297	$	5,745		$	297
Weighted-average remaining lease term					72 months			12 months
Weighted-average discount rate					8.5		%	8.0		%

As of June 30, 2024, future minimum lease payments under non-cancelable capitalized operating leases were as follows (in thousands):


2024 (remainder)	$	—
2025	1,382
2026	1,551
2027	1,598
2028	1,646
Thereafter	2,555
Total operating lease payments	8,732
Less imputed interest	(2,083)
Less fixed asset receivable	(980)
Present value of operating lease liabilities	$	5,669

Net Income Per Share

6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Net Income Per Share

We compute our basic and diluted net income per share in conformity with the two-class method required for companies with participating shares. Under the two-class method, net income is determined by allocating net income between common stock and unvested RSAs. We compute basic net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period. We compute diluted net income per share by dividing our net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, including potentially dilutive stock options and unvested restricted stock units (“RSUs”), less unvested RSAs. We use the treasury stock method to determine the number of dilutive shares of common stock resulting from stock options and unvested RSUs.

The following table shows the computation of net income per share for each period:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

	(in thousands, except per share amounts)
Numerator:
Net income attributable to common stockholders	$	35,120	$	27,356	$	62,640	$	43,173
Denominator:
Weighted-average shares used to compute basic net income per common share	103,118		101,964		102,954		104,908
Dilutive effect of employee stock options and unvested RSUs	8,126		7,626		7,596		7,584
Weighted-average shares used to compute diluted net income per common share	111,244		109,590		110,550		112,492

Basic net income per common share	$	0.34	$	0.27	$	0.61	$	0.41

Diluted net income per common share	$	0.32	$	0.25	$	0.57	$	0.38

As of June 30, 2024, we had 25.8 million stock options, 1.1 million RSAs and 0.1 million RSUs outstanding. As of June 30, 2023, we had 24.3 million stock options, 0.1 million RSUs and 0.7 million RSAs outstanding.

We excluded from the computation of diluted net income per share, on a weighted-average basis, 9.5 million and 9.8 million stock options and unvested RSUs outstanding during the three and six months ended June 30, 2024, respectively, and 9.5 million and 9.2 million stock options and unvested RSUs outstanding during the three and six months ended June 30, 2023, respectively, because including them would have reduced dilution.

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2024	Jul. 22, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	000-50679
Entity Registrant Name	CORCEPT THERAPEUTICS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0487658
Entity Address, Address Line One	149 Commonwealth Drive
Entity Address, City or Town	Menlo Park
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94025
City Area Code	650
Local Phone Number	327-3270
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	CORT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		104,492,469
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001088856
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Unrealized (loss) gain on available-for-sale investments, tax expense (benefit)	$ 14	$ (23)	$ 117	$ (215)

Composition of Certain Balance Sheet Items - Narrative (Details) $ in Millions	Jun. 30, 2024 USD ($) manufacturer	Dec. 31, 2023 USD ($)
Balance Sheet Related Disclosures [Abstract]
Number of manufacturers \| manufacturer	2
Deposits for clinical trials \| $	$ 5.9	$ 6.4

Composition of Certain Balance Sheet Items (Tables)

6 Months Ended

Jun. 30, 2024

Balance Sheet Related Disclosures [Abstract]

Schedule of composition of inventory, current

Inventory


	June 30, 2024		December 31, 2023

	(in thousands)
Work in progress	8,451		8,233
Finished goods	8,350		7,741
Total inventory	16,801		15,974
Less strategic inventory classified as non-current	(8,451)		(8,244)
Total inventory classified as current	$	8,350	$	7,730

Schedule of composition of inventory, noncurrent

Inventory


	June 30, 2024		December 31, 2023

	(in thousands)
Work in progress	8,451		8,233
Finished goods	8,350		7,741
Total inventory	16,801		15,974
Less strategic inventory classified as non-current	(8,451)		(8,244)
Total inventory classified as current	$	8,350	$	7,730

Schedule of prepaid expenses and other current assets

Prepaid expenses and other current assets


	June 30, 2024		December 31, 2023

	(in thousands)
Deferred clinical materials	$	8,328	$	13,496
Prepaid expenses	5,146		4,319
Clinical deposits	2,903		3,865
Other current assets	9,126		5,882
Total prepaid expenses and other current assets	$	25,503	$	27,562

Schedule of other accrued liabilities

Accrued and other liabilities


	June 30, 2024		December 31, 2023

	(in thousands)
Government rebates	$	31,651	$	18,468
Accrued compensation	17,392		25,457
Accrued selling and marketing costs	3,535		1,771
Legal fees	1,376		542
Other	5,296		5,390
Total accrued and other liabilities	$	59,250	$	51,628

Available-for-Sale Marketable Securities and Fair Value Measurements - Schedule of Available-for-Sale Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 459,601	$ 387,016
Estimate of fair value measurement
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	459,710	386,641
Gross Unrealized Gains	27	388
Gross Unrealized Losses	(136)	(13)
Estimated Fair Value	459,601	387,016
Estimate of fair value measurement \| Corporate bonds \| Level 2
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	176,998	120,508
Gross Unrealized Gains	26	307
Gross Unrealized Losses	(119)	0
Estimated Fair Value	176,905	120,815
Estimate of fair value measurement \| Commercial paper \| Level 2
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	29,653	75,308
Gross Unrealized Gains	0	20
Gross Unrealized Losses	(9)	(9)
Estimated Fair Value	29,644	75,319
Estimate of fair value measurement \| U.S. Treasury securities \| Level 1
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	172,304	93,655
Gross Unrealized Gains	1	61
Gross Unrealized Losses	(8)	(4)
Estimated Fair Value	172,297	93,712
Estimate of fair value measurement \| Money market funds \| Level 1
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	80,755	97,170
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Estimated Fair Value	$ 80,755	$ 97,170

Composition of Certain Balance Sheet Items - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred clinical materials	$ 8,328	$ 13,496
Prepaid expenses	5,146	4,319
Clinical deposits	2,903	3,865
Other current assets	9,126	5,882
Prepaid expenses and other current assets	$ 25,503	$ 27,562

Stockholders' Equity - Summary of Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Capitalized stock-based compensation	$ 83	$ 34	$ 128	$ 126
Total stock-based compensation	15,290	11,892	28,584	23,125
Cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	14	9	25	32
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	4,437	3,661	8,358	7,145
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense	$ 10,756	$ 8,188	$ 20,073	$ 15,822

Net Income Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Restricted Stock Units and Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average options excluded from the computation of diluted net income per share (in shares)	9.5	9.5	9.8	9.2
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options outstanding (in shares)	25.8	24.3	25.8	24.3
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity instruments other than options, outstanding (in shares)	0.1	0.1	0.1	0.1
Restricted Stock Awards (RSAs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Equity instruments other than options, outstanding (in shares)	1.1	0.7	1.1	0.7

Commitments and Contingencies (Details) - USD ($)	Feb. 08, 2023	Jun. 30, 2024
Loss Contingencies [Line Items]
Other losses for contingent liability		$ 0
Other provisions for a loss contingency		$ 0
Melucci \| Settled Litigation
Loss Contingencies [Line Items]
Payment awarded to other party	$ 14,000,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 35,488	$ 27,762	$ 27,528	$ 15,879	$ 63,250	$ 43,407

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Net Income Per Share (Tables)

6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Schedule of computation of net income per share

The following table shows the computation of net income per share for each period:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

	(in thousands, except per share amounts)
Numerator:
Net income attributable to common stockholders	$	35,120	$	27,356	$	62,640	$	43,173
Denominator:
Weighted-average shares used to compute basic net income per common share	103,118		101,964		102,954		104,908
Dilutive effect of employee stock options and unvested RSUs	8,126		7,626		7,596		7,584
Weighted-average shares used to compute diluted net income per common share	111,244		109,590		110,550		112,492

Basic net income per common share	$	0.34	$	0.27	$	0.61	$	0.41

Diluted net income per common share	$	0.32	$	0.25	$	0.57	$	0.38

Basis of Presentation and Summary of Significant Accounting Policies (Details) compound in Thousands	6 Months Ended
	Jun. 30, 2024 series compound
Accounting Policies [Abstract]
Number of series of selective cortisol modulators \| series	4
Number of compounds (more than) \| compound	1

Net Income Per Share - Schedule of Computation of Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator:
Net income attributable to common stockholders basic	$ 35,120	$ 27,356	$ 62,640	$ 43,173
Net income attributable to common stockholders diluted	$ 35,120	$ 27,356	$ 62,640	$ 43,173
Denominator:
Weighted-average shares used to compute basic net income per common share (in shares)	103,118	101,964	102,954	104,908
Dilutive effect of employee stock options and unvested RSUs (in shares)	8,126	7,626	7,596	7,584
Weighted-average shares used to compute diluted net income per common share (in shares)	111,244	109,590	110,550	112,492
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic net income per common share (in dollars per share)	$ 0.34	$ 0.27	$ 0.61	$ 0.41
Diluted net income per common share (in dollars per share)	$ 0.32	$ 0.25	$ 0.57	$ 0.38

Stockholders' Equity

6 Months Ended

Jun. 30, 2024

Equity [Abstract]

Stockholders’ Equity

Treasury Stock

In January 2024, our Board of Directors approved a program authorizing the repurchase of up to $200 million of our common stock (the “Stock Repurchase Program”). Purchases under this program may be made in the open market, in privately negotiated transactions or otherwise. The timing and amount of any repurchases will be determined based on market conditions, our stock price and other factors. The program does not require us to repurchase any specific number of shares of its common stock and may be modified, suspended or discontinued at any time without notice.

During each of the three and six months ended June 30, 2024, we purchased 0.1 million shares of our common stock under the Stock Repurchase Program in open market transactions at an average price of $28.61 and $27.93 per share, respectively, for aggregate purchase prices of $3.5 million and $4.0 million, respectively. As of June 30, 2024, $196.0 million of the current authorization remained available for the repurchase of shares of our common stock.

We recorded purchased shares as treasury stock on our condensed consolidated balance sheets at cost. As of June 30, 2024 and December 31, 2023, we had 31.5 million and 30.9 million treasury shares outstanding, respectively.

Incentive Award Plan

We have one equity award plan – the Corcept Therapeutics Incorporated 2024 Incentive Award Plan (the “2024 Plan”).

In February 2024, our Board of Directors approved the 2024 Plan, which became effective upon its approval by our stockholders at our 2024 Annual Meeting of Stockholders on May 17, 2024 and replaced the Corcept Therapeutics Incorporated 2012 Incentive Award Plan (the “2012 Plan”). The aggregate number of shares which may be issued or transferred pursuant to awards under the 2024 Plan is equal to the sum of (i) 8.0 million shares, (ii) 4.1 million shares, which equals the number of shares available for future grant under the 2012 Plan as of May 17, 2024, and (iii) any shares underlying awards outstanding under the 2012 Plan that, on or after May 17, 2024, terminate, expire or lapse for any reason without the delivery of shares to the holder thereof. After May 17, 2024, no additional awards were or will be issued under the 2012 Plan.

Under the 2024 Plan, we can issue stock options, stock purchase and stock appreciation rights and restricted stock awards to our employees, officers, directors and consultants.

Stock Options

During the three and six months ended June 30, 2024, we issued 0.5 million and 0.8 million, respectively, shares of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the then current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the three and six months ended June 30, 2024, we purchased 0.2 million and 0.3 million shares, respectively, in connection with such option net exercises and paid $0.8 million and $1.6 million, respectively, to satisfy associated tax withholding obligations.

During the three and six months ended June 30, 2023, we issued 0.4 million and 1.0 million, respectively, shares of our common stock upon the exercise of stock options. Some option holders exercised their options on a “net exercise” basis, pursuant to which they surrendered to us, and we purchased from them, at the then current market price, shares equal in value to the associated exercise price and tax withholding obligations. During the three and six months ended June 30, 2023, we

purchased 0.2 million and 0.5 million shares, respectively, in connection with such option net exercises and paid $1.5 million and $2.6 million, respectively, to satisfy associated tax withholding obligations.

Restricted Stock Awards (“RSAs”)

During the three and six months ended June 30, 2024, we granted employees 0.2 million and 0.6 million RSAs, respectively, with a weighted-average grant date fair value of $28.24 and $24.89 per share, respectively. During the three and six months ended June 30, 2023, we granted employees 0.1 million and 0.4 million RSAs with a weighted-average grant date fair value of $22.80 and $22.50 per share, respectively. RSAs include voting and dividend rights and are therefore “participating” shares for the purpose of calculating basic and diluted net income per share. See “Note 7” below.

Employee Stock Purchase Plan (“ESPP”)

Our ESPP allows employees to set aside, by means of payroll deductions, up to ten percent of their annual compensation for the purchase of our common stock. Shares are issued to participating employees from the 2024 Plan on March 1st, June 1st, September 1st and December 1st (or, if those dates fall on holidays or weekends, on the first business day thereafter) at the then-current fair market value of our stock, as determined at the close of trading on those days.

For each purchased share, the participating employee receives one matching share, also issued from the 2024 Plan if certain conditions are met. There is no vesting requirement for shares issued pursuant to the ESPP purchase. The matching share will be granted in the form of an RSA that will vest on the one-year anniversary of the respective ESPP purchase date, net of applicable tax withholding. The vesting condition on the RSA is that the participating employee hold the corresponding share purchased under the ESPP for one year from the purchase date. Shares purchased pursuant to the ESPP and any matching shares issued upon satisfaction of the one-year holding requirement may be held, sold or transferred at the employee’s sole discretion.

As of June 30, 2024 and December 31, 2023, we had a liability of $1.5 million and $2.3 million, respectively, of stock-based compensation related to RSAs granted in connection with our ESPP in “Accrued and other liabilities” on our unaudited condensed consolidated balance sheets.

Stock-based Compensation

The following table summarizes our stock-based compensation by account:


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023

	(in thousands)
Capitalized stock-based compensation	$	83	$	34	$	128	$	126
Cost of sales	14		9		25		32
Research and development	4,437		3,661		8,358		7,145
Selling, general and administrative	10,756		8,188		20,073		15,822
Total stock-based compensation	$	15,290	$	11,892	$	28,584	$	23,125

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Stockholders' Equity - Narrative (Details) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 29, 2024 shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) plan $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) shares	Jan. 31, 2024 USD ($)
Shareholders Equity [Line Items]
Purchase price of stock repurchase \| $				$ 3,954	$ 0
Number of stock option plans \| plan				1
Number of shares authorized (in shares) \| shares	8.0
Increase in shares authorized for grant (in shares) \| shares	4.1
Payment tax withholding share-based payment arrangement \| $				$ 3,665	$ 3,052
Employee Stock Option
Shareholders Equity [Line Items]
Treasury stock (in shares) \| shares		31.5		31.5		30.9
Issuance of common stock under our incentive award plan (in shares) \| shares		0.5	0.4	0.8	1.0
Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock (in shares) \| shares		0.2	0.2	0.3	0.5
Payment tax withholding share-based payment arrangement \| $		$ 800	$ 1,500	$ 1,600	$ 2,600
Restricted Stock Awards (RSAs)
Shareholders Equity [Line Items]
Grants in period (in shares) \| shares		0.2	0.1	0.6	0.4
Weighted average grant date fair value (in dollars per share) \| $ / shares		$ 28.24	$ 22.80	$ 24.89	$ 22.50
Allocated share-based compensation expense \| $				$ 1,500		$ 2,300
Employee Stock
Shareholders Equity [Line Items]
ESPP maximum employee subscription rate		10.00%		10.00%
Award vesting period				1 year
Stock Repurchase Program
Shareholders Equity [Line Items]
Repurchase of common stock in connection with Stock Repurchase Program (in shares) \| shares		0.1		0.1
Common stock repurchased, average price (in dollars per share) \| $ / shares		$ 28.61		$ 27.93
Purchase price of stock repurchase \| $		$ 3,500		$ 4,000
Stock repurchase program, remaining authorized amount available for repurchase \| $		$ 196,000		$ 196,000
Stock Repurchase Program \| Common Stock
Shareholders Equity [Line Items]
Stock repurchase amount \| $							$ 200,000

Leases - Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
2024 (remainder)	$ 0
2025	1,382
2026	1,551
2027	1,598
2028	1,646
Thereafter	2,555
Total operating lease payments	8,732
Less imputed interest	(2,083)
Present value of operating lease liabilities	5,669
Operating Lease, Lease Not yet Commenced
Unrecorded Unconditional Purchase Obligation [Line Items]
Less fixed asset receivable	$ (980)

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Product revenue, net	$ 163,796	$ 117,715	$ 310,604	$ 223,369
Operating expenses:
Cost of sales	2,524	1,574	5,059	2,960
Research and development	58,745	43,277	117,251	84,128
Selling, general and administrative	66,935	43,281	123,203	91,845
Total operating expenses	128,204	88,132	245,513	178,933
Income from operations	35,592	29,583	65,091	44,436
Interest and other income	6,004	3,347	11,498	6,928
Income before income taxes	41,596	32,930	76,589	51,364
Income tax expense	(6,108)	(5,402)	(13,339)	(7,957)
Net income	35,488	27,528	63,250	43,407
Net income attributable to common stockholders basic	35,120	27,356	62,640	43,173
Net income attributable to common stockholders diluted	$ 35,120	$ 27,356	$ 62,640	$ 43,173
Basic net income per common share (in dollars per share)	$ 0.34	$ 0.27	$ 0.61	$ 0.41
Diluted net income per common share (in dollars per share)	$ 0.32	$ 0.25	$ 0.57	$ 0.38
Weighted-average shares outstanding used in computing net income per common share
Basic (in shares)	103,118	101,964	102,954	104,908
Diluted (in shares)	111,244	109,590	110,550	112,492

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net income	$ 63,250	$ 43,407
Adjustments to reconcile net income to net cash provided by operations:
Stock-based compensation	28,456	22,999
Accretion of discount on marketable securities, net	(5,881)	(3,180)
Depreciation and amortization	196	596
Deferred income taxes	(21,126)	(16,964)
Amortization of right-of-use asset	181	1,205
Changes in operating assets and liabilities:
Trade receivables	(12,714)	(1,496)
Insurance recovery receivable related to Melucci litigation	14,000	0
Inventory	(698)	1,480
Prepaid expenses and other current assets	1,868	973
Other assets	(398)	0
Accounts payable	1,729	(3,802)
Accrued research and development expenses	642	4,034
Accrued and other liabilities	7,907	19,279
Accrued settlement related to Melucci litigation	(14,000)	0
Long-term accrued income taxes	1,630	855
Operating lease liability	(104)	(1,143)
Net cash provided by operating activities	64,938	68,243
Cash flows from investing activities:
Purchases of property and equipment	(416)	(102)
Proceeds from maturities of marketable securities	151,812	272,295
Purchases of marketable securities	(220,604)	(88,815)
Net cash (used in) provided by investing activities	(69,208)	183,378
Cash flows from financing activities:
Proceeds from issuance of common stock under our incentive award plan, net of issuance costs	2,288	652
Proceeds from purchases under the Employee Stock Purchase Program	2,638	2,255
Repurchase of common stock in connection with Stock Repurchase Program	(3,954)	0
Repurchase of common stock in connection with Tender Offer	0	(145,428)
Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants	(3,665)	(3,052)
Net cash used in financing activities	(2,693)	(145,573)
Net (decrease) increase in cash and cash equivalents	(6,963)	106,048
Cash and cash equivalents, at beginning of period	135,551	66,329
Cash and cash equivalents, at end of period	128,588	172,377
Supplemental disclosure:
Exercise cost of shares repurchased for net settlement of cashless option exercises	$ 6,131	$ 8,532

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies There have been no material changes in our obligations under contractual agreements described in our Annual Report on Form 10-K for the year ended December 31, 2023. In the ordinary course of business, we may be subject to legal claims and regulatory actions that could have a material adverse effect on our business or financial position. We assess our potential liability in such situations by analyzing potential outcomes under various litigation, regulatory and settlement strategies. If we determine a loss is probable and its amount can be reasonably estimated, we accrue an amount equal to the estimated loss. Melucci Litigation and Settlement On March 14, 2019, a purported securities class action complaint was filed in the United States District Court for the Northern District of California by Nicholas Melucci (Melucci v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). The complaint named us and certain of our executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleges that the defendants made false and materially misleading statements and failed to disclose adverse facts about our business, operations and prospects. The complaint asserts a putative class period extending from August 2, 2017 to February 5, 2019 and seeks unspecified monetary relief, interest and attorneys’ fees. On October 7, 2019, the Court appointed a lead plaintiff and lead counsel. The lead plaintiff’s consolidated complaint was filed on December 6, 2019. On February 8, 2023, we reached an agreement in principle (the “Proposed Settlement”) to resolve all claims in the Melucci litigation. As previously disclosed, we made a one-time payment of $14.0 million into escrow as required by the Proposed Settlement and our insurers have since reimbursed us in full for this payment. On June 6, 2024, Judge James Donato of the United States District Court for the Northern District of California granted final approval of the Proposed Settlement which will govern administration of payments to eligible members of the plaintiff class. No losses and no provision for a loss contingency have been recorded to date. For further information about our ongoing legal matters, see Part II. Item 1, Legal Proceedings.

Composition of Certain Balance Sheet Items - Schedule of Composition of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Work in progress	$ 8,451	$ 8,233
Finished goods	8,350	7,741
Total inventory	16,801	15,974
Less strategic inventory classified as non-current	(8,451)	(8,244)
Total inventory classified as current	$ 8,350	$ 7,730

Leases - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended
Leases - Narrative (Details) $ in Millions	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Apr. 12, 2024 USD ($) ft²
Leases [Abstract]
Term of contract					6 years
Rentable area \| ft²					50,632
Obligated base rent					$ 1.5
Operating lease expenses	$ 0.8	$ 0.6	$ 1.4	$ 1.2

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We recorded income tax expense of $6.1 million and $13.3 million for the three and six months ended June 30, 2024, respectively, as compared to an income tax expense of $5.4 million and $8.0 million for the three and six months ended June 30, 2023. The increase during the three and six months ended June 30, 2024 was primarily due to increased pretax book income compared to the corresponding period in 2023. Our effective tax rate differs from the federal statutory rate due to state income taxes and the non-deductible portion of our stock-based compensation, which increased our tax expense, offset by research and development credits and the excess tax deduction arising from the exercise of employee stock options, which reduced our taxable income. During the three and six months ended June 30, 2024, unrecognized tax benefits increased by $1.4 million and $2.0 million, respectively. Each quarter, we assess the likelihood that we will generate sufficient taxable income to use our federal and state deferred tax assets. Except for the valuation allowances that offset the value of our California net deferred tax assets, we have determined that it is more likely than not we will realize the benefit related to all other deferred tax assets. To the extent we increase a valuation allowance, we will include an expense in the Condensed Consolidated Statement of Income in the period in which such determination is made. Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the right to deduct research and development expenditures for tax purposes in the period the expenses were incurred and instead requires all U.S. and foreign research and development expenditures to be amortized over five and fifteen tax years, respectively. Congress has considered legislation that would defer the amortization requirement to later years, but as of June 30, 2024, the requirement has not been modified.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Leases (Tables)

6 Months Ended

Jun. 30, 2024

Leases [Abstract]

Schedule of information of leases asset and liabilities

was as follows (in thousands, except weighted average amounts):


	Three months ended June 30,				Six months ended June 30,
	2024		2023		2024			2023
Cash paid for operating lease liabilities	$	741	$	578	$	1,358		$	1,157
Recognition of right-of-use asset in exchange for lease liability	$	5,745	$	297	$	5,745		$	297
Weighted-average remaining lease term					72 months			12 months
Weighted-average discount rate					8.5		%	8.0		%

Schedule of future minimum lease payments under non-cancelable operating leases

As of June 30, 2024, future minimum lease payments under non-cancelable capitalized operating leases were as follows (in thousands):


2024 (remainder)	$	—
2025	1,382
2026	1,551
2027	1,598
2028	1,646
Thereafter	2,555
Total operating lease payments	8,732
Less imputed interest	(2,083)
Less fixed asset receivable	(980)
Present value of operating lease liabilities	$	5,669

Available-for-Sale Marketable Securities and Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Interest receivable, current	$ 2.3	$ 1.7
Marketable securities, maximum maturity period	26 months
Marketable securities, short-term, maximum maturity period	1 year
Weighted average maturity period	4 months
Minimum
Debt Securities, Available-for-sale [Line Items]
Long-term marketable securities remaining maturity	13 months
Maximum
Debt Securities, Available-for-sale [Line Items]
Long-term marketable securities remaining maturity	18 months

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

+ Details

Available-for-Sale Marketable Securities and Fair Value Measurements - Summary of the Classification of Available-for-Sale Securities in Condensed Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Total marketable securities	$ 459,601	$ 387,016
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Total marketable securities	95,718	97,170
Short-term marketable securities
Debt Securities, Available-for-sale [Line Items]
Total marketable securities	344,568	232,670
Long-term marketable securities
Debt Securities, Available-for-sale [Line Items]
Total marketable securities	$ 19,315	$ 57,176

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Description of Business and Basis of Presentation Corcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us,” and “our”) is a commercial-stage pharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym (“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. In June 2024, we made available an authorized generic version of Korlym for the same indication. We have discovered and patented four structurally distinct series of selective cortisol modulators, consisting of more than 1,000 compounds. We are developing compounds from these series as potential treatments for a broad range of serious disorders. We were incorporated in the State of Delaware in May 1998. Our headquarters are located in Menlo Park, California. Basis of Presentation We have prepared the following interim financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X: (i) condensed consolidated balance sheet as of June 30, 2024 and (ii) condensed consolidated statements of income, comprehensive income and stockholders’ equity for the three- and six-month periods ended June 30, 2024 and 2023 and (iii) condensed consolidated statements of cash flows for the six-month periods ended June 30, 2024 and 2023. These do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation (which in the applicable periods consist only of normal, recurring adjustments) have been included. Operating results for the three- and six-month periods ended June 30, 2024 are not necessarily indicative of the results for the remainder of 2024 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2023 included in our Annual Report on Form 10-K. The December 31, 2023 balance sheet was derived from audited financial statements at that date. There have been no material changes to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2023. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public companies with annual periods beginning after December 15, 2024, with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2025. We are currently evaluating the effects adoption of this guidance will have on the condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, to improve the disclosures about a public entity’s reportable segments and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The standard is effective for public companies with annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. We plan to adopt this guidance for the fiscal year ending December 31, 2024. We are currently evaluating the effects adoption of this guidance will have on the condensed consolidated financial statements.

Leases - Right-of-use Assets and Related Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Cash paid for operating lease liabilities	$ 741	$ 578	$ 1,358	$ 1,157
Recognition of right-of-use asset in exchange for lease liability	$ 5,745	$ 297	$ 5,745	$ 297
Weighted-average remaining lease term	72 months	12 months	72 months	12 months
Weighted-average discount rate	8.50%	8.00%	8.50%	8.00%

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 6,108	$ 5,402	$ 13,339	$ 7,957
Unrecognized tax benefits, period increase	$ 1,400		$ 2,000

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Composition of Certain Balance Sheet Items - Schedule of Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Government rebates	$ 31,651	$ 18,468
Accrued compensation	17,392	25,457
Accrued selling and marketing costs	3,535	1,771
Legal fees	1,376	542
Other	5,296	5,390
Total accrued and other liabilities	$ 59,250	$ 51,628

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 35,488	$ 27,528	$ 63,250	$ 43,407
Other comprehensive income (loss):
Unrealized (loss) gain on available-for-sale investments, net of tax effect of $14, $(23), $117 and $(215), respectively	(189)	75	(519)	680
Foreign currency translation gain (loss), net of tax	15	123	(6)	234
Total comprehensive income	$ 35,314	$ 27,726	$ 62,725	$ 44,321

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details